The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202425206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von John G Woodland und 33 weiteren Autor:innen. Beteiligte Einrichtung: Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa. Hauptthemen laut MEDLINE: Plasmodium falciparum, Protein Kinase Inhibitors, Antimalarials, 1-Phosphatidylinositol 4-Kinase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Innovation (SAMRC-GIPD) Drug Discovery for Malaria Elimination, Medicines for Malaria Venture, NIAID NIH HHS.
Abstract (Originalsprache)
New compounds targeting human malaria parasites are critical for effective malaria control and elimination. Here, we pursued the imidazoquinolinone AZD0156 (MMV1580483), a human ataxia‐telangiectasia mutated (ATM) kinase inhibitor that completed Phase I clinical trials as an anticancer agent. We validated its in vitro activity against the two main forms of the Plasmodium falciparum parasite in the human host, viz. the asexual blood (symptomatic) stage and sexual gametocyte (transmission) stage. Resistance selection, cross‐resistance, biochemical, and conditional knockdown studies revealed that AZD0156 inhibits P. falciparum phosphatidylinositol 4‐kinase type III beta ( Pf PI4Kβ), a clinically‐validated target for the treatment of malaria. Metabolic perturbations, fixed‐ratio isobolograms, killing kinetics and morphological evaluation correlated AZD0156 inhibition with other known PI4Kβ inhibitors. The compound showed favorable in vivo pharmacokinetic properties and 81% antimalarial efficacy (4 × 50 mg kg −1 ) in a P. berghei mouse malaria infection model. Importantly, a cleaner biochemical profile was measured against human kinases (MAP4K4, MINK1) implicated in embryofoetal developmental toxicity associated with the Pf PI4Kβ inhibitor MMV390048. This improved kinase selectivity profile and structural differentiation from other PI4Kβ inhibitors, together with its multistage antiplasmodial activity and favorable pharmacokinetic properties, makes AZD0156 an attractive candidate for target‐based drug repositioning against malaria via a medicinal chemistry optimization approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
- South African Medical Research Council Drug Discovery and Development Research Unit, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 7925, South Africa.
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa.
- Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028, South Africa.
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Förderung
- Department of Science and Innovation (SAMRC-GIPD) Drug Discovery for Malaria Elimination
- Medicines for Malaria Venture
- NIAID NIH HHS
- Gates Foundation
- The Department of Science and Innovation and the National Research Foundation South African Research Chair
- the UK Government's Global Challenges Research to L.B.C. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health to K.J.…
- Future Leaders-African Independent Research (FLAIR)
- South African Medical Research Council
Zitieren
APA
Woodland, J. G., Coertzen, D., Wicht, K. J., Hidalgo, V. F., Pasaje, C. F. A., Godoy, L. C., Qahash, T., Mmonwa, M. M., Dziwornu, G. A., Wambua, L., Harries, S., Korkor, C. M., Njoroge, M., Krugmann, L., Taylor, D., Leshabane, M., Langeveld, H., Rabie, T., Reader, J., …, & Chibale, K. (2025). The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202425206
Vancouver
Woodland JG, Coertzen D, Wicht KJ, Hidalgo VF, Pasaje CFA, Godoy LC, et al. The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202425206
BibTeX
@article{Woodland2025,
author = {Woodland, John G and Coertzen, Dina and Wicht, Kathryn J and Hidalgo, Virginia Franco and Pasaje, Charisse Flerida A and Godoy, Luiz C and Qahash, Tarrick and Mmonwa, Mmakwena M and Dziwornu, Godwin A and Wambua, Lynn and Harries, Sarah and Korkor, Constance M and Njoroge, Mathew and Krugmann, Liezl and Taylor, Dale and Leshabane, Meta and Langeveld, Henrico and Rabie, Tayla and Reader, Janette and van der Watt, Mariëtte and Venter, Nelius and Erlank, Erica and Aswat, Ayesha S and Koekemoer, Lizette L and Yeo, Tomas and Jeon, Jin H and Fidock, David A and Gamo, Francisco Javier and Wittlin, Sergio and Niles, Jacquin C and Llinas, Manuel and Coulson, Lauren B and Birkholtz, Lyn-Marié and Chibale, Kelly},
title = {The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202425206}
}
EUVIMED